Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial
Xin-Yi Zhang
Department of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China
Search for more papers by this authorLang Lv
Department of Drug Research, State Key Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou, China
Search for more papers by this authorYu-Long Zhou
Department of Respiratory Diseases, The Ninth Hospital of Nanchang, Nanchang, China
Search for more papers by this authorLiang-Dong Xie
Department of Critical Care Medicine, The Fifth People's Hospital of Ganzhou, Ganzhou, China
Search for more papers by this authorQin Xu
Department of Respiratory Diseases, Fengcheng People's Hospital, Fengcheng, China
Search for more papers by this authorXiao-Fan Zou
Department of Respiratory Diseases, Ji'an Central People's Hospital, Ji'an, China
Search for more papers by this authorYan Ding
Department of Respiratory Diseases, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China
Search for more papers by this authorJie Tian
Department of Respiratory Diseases, The Ninth Hospital of Nanchang, Nanchang, China
Search for more papers by this authorJia-Liang Fan
Department of Respiratory Diseases, Ji'an Central People's Hospital, Ji'an, China
Search for more papers by this authorHai-Wei Fan
Department of Drug Research, State Key Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou, China
Search for more papers by this authorYi-Xi Yang
Department of Drug Research, State Key Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou, China
Search for more papers by this authorCorresponding Author
Xiao-Qun Ye
Department of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China
Correspondence
Xiao-Qun Ye, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang 330006, Jiangxi, China.
Email: [email protected]
Search for more papers by this authorXin-Yi Zhang
Department of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China
Search for more papers by this authorLang Lv
Department of Drug Research, State Key Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou, China
Search for more papers by this authorYu-Long Zhou
Department of Respiratory Diseases, The Ninth Hospital of Nanchang, Nanchang, China
Search for more papers by this authorLiang-Dong Xie
Department of Critical Care Medicine, The Fifth People's Hospital of Ganzhou, Ganzhou, China
Search for more papers by this authorQin Xu
Department of Respiratory Diseases, Fengcheng People's Hospital, Fengcheng, China
Search for more papers by this authorXiao-Fan Zou
Department of Respiratory Diseases, Ji'an Central People's Hospital, Ji'an, China
Search for more papers by this authorYan Ding
Department of Respiratory Diseases, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China
Search for more papers by this authorJie Tian
Department of Respiratory Diseases, The Ninth Hospital of Nanchang, Nanchang, China
Search for more papers by this authorJia-Liang Fan
Department of Respiratory Diseases, Ji'an Central People's Hospital, Ji'an, China
Search for more papers by this authorHai-Wei Fan
Department of Drug Research, State Key Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou, China
Search for more papers by this authorYi-Xi Yang
Department of Drug Research, State Key Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou, China
Search for more papers by this authorCorresponding Author
Xiao-Qun Ye
Department of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China
Correspondence
Xiao-Qun Ye, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang 330006, Jiangxi, China.
Email: [email protected]
Search for more papers by this authorXin-Yi Zhang, Lang Lv, Yu-Long Zhou, Liang-Dong Xie, Qin Xu, Xiao-Fan Zou and Yan Ding contributed equally to this work.
Funding information: The Key Projects of Jiangxi Province, Grant/Award Number: 2020YBBGW0008
Abstract
Xiyanping (XYP) is a Chinese herbal medicine used in the clinic to treat respiratory infection and pneumonia. Recent evidence identified XYP as a potential inhibitor of severe acute respiratory syndrome coronavirus 2, implying XYP as a possible treatment for the coronavirus disease 2019 (COVID-19). Here, we conducted a prospective, multicenter, open-label and randomized controlled trial to evaluate the safety and effectiveness of XYP injection in patients with mild to moderate COVID-19. We consecutively recruited 130 COVID-19 patients with mild to moderate symptoms from five study sites, and randomized them in 1:1 ratio to receive XYP injection in combination with standard therapy or receive standard supportive therapy alone. We found that XYP injection significantly reduced the time to cough relief, fever resolution and virus clearance. Less patients receiving XYP injection experienced disease progression to the severe stage during the treatment process. No severe adverse events were reported during the study. Taken together, XYP injection is safe and effective in improving the recovery of patients with mild to moderate COVID-19. However, further studies are warranted to evaluate the efficacy of XYP in an expanded cohort comprising COVID-19 patients at different disease stages.
CONFLICT OF INTEREST
The authors declare no conflicts of interest.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| ptr7141-sup-0001-Supinfo.docxWord 2007 document , 147.9 KB | Figure S1. The dynamics of C-reactive protein in treatment group (red line) and control group (blue line). Table S1. The main ingredients of Andrographis paniculate and Xiyanping. Table S2. All adverse events. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., … Hullsiek, K. H. (2020). A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. The New England Journal of Medicine, 383(6), 517–525. https://doi.org/10.1056/NEJMoa2016638
- Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., … Wang, C. (2020). A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. The New England Journal of Medicine, 382(19), 1787–1799. https://doi.org/10.1056/NEJMoa2001282
- Chandramohan, V., Kaphle, A., Chekuri, M., Gangarudraiah, S., & Bychapur Siddaiah, G. (2015). Evaluating andrographolide as a potent inhibitor of NS3-4A protease and its drug-resistant mutants using in silico approaches. Advances in Virology, 2015, 972067. https://doi.org/10.1155/2015/972067
- Chang, R. S., Ding, L., Chen, G. Q., Pan, Q. C., Zhao, Z. L., & Smith, K. M. (1991). Dehydroandrographolide succinic acid monoester as an inhibitor against the human immunodeficiency virus. Proceedings of the Society for Experimental Biology and Medicine, 197(1), 59–66. https://doi.org/10.3181/00379727-197-43225
- Chong, L., Chen, W., Luo, Y., & Jiang, Z. (2013). Simultaneous determination of 9-dehydro-17-hydro-andrographolide and sodium 9-dehydro-17-hydro-andrographolide-19-yl sulfate in rat plasma by UHPLC-ESI-MS/MS after administration of xiyanping injection: Application to a pharmacokinetic study. Biomedical Chromatography, 27(7), 825–830. https://doi.org/10.1002/bmc.2866
- Enmozhi, S. K., Raja, K., Sebastine, I., & Joseph, J. (2020). Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: An in silico approach. Journal of Biomolecular Structure & Dynamics, 1–7. https://doi.org/10.1080/07391102.2020.1760136
- Guo, W., Liu, W., Chen, G., Hong, S., Qian, C., Xie, N., … Xu, Q. (2012). Water-soluble andrographolide sulfonate exerts anti-sepsis action in mice through down-regulating p38 MAPK, STAT3 and NF-κB pathways. International Immunopharmacology, 14(4), 613–619. https://doi.org/10.1016/j.intimp.2012.09.002
- Gupta, S., Mishra, K. P., & Ganju, L. (2017). Broad-spectrum antiviral properties of andrographolide. Archives of Virology, 162(3), 611–623. https://doi.org/10.1007/s00705-016-3166-3
- Hu, K., Guan, W. J., Bi, Y., Zhang, W., Li, L., Zhang, B., … Zhong, N. S. (2021). Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine, 85, 153242. https://doi.org/10.1016/j.phymed.2020.153242
- Huang, Y. F., Bai, C., He, F., Xie, Y., & Zhou, H. (2020). Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19). Pharmacological Research, 158, 104939. https://doi.org/10.1016/j.phrs.2020.104939
- Li, M., Yang, X., Guan, C., Wen, T., Duan, Y., Zhang, W., … Liu, S. (2018). Andrographolide sulfonate reduces mortality in Enterovirus 71 infected mice by modulating immunity. International Immunopharmacology, 55, 142–150. https://doi.org/10.1016/j.intimp.2017.11.042
- Li, Q., Li, Z. Y., Zhang, J., Guo, W. N., Xu, X. M., Sun, F. X., & Xu, H. (2019). Xiyanping plus azithromycin chemotherapy in pediatric patients with mycoplasma pneumoniae pneumonia: A systematic review and meta-analysis of efficacy and safety. Evidence-based Complementary and Alternative Medicine, 2019, 2346583. https://doi.org/10.1155/2019/2346583
- Li, Y., He, S., Tang, J., Ding, N., Chu, X., Cheng, L., … Wu, J. (2017). Andrographolide inhibits inflammatory cytokines secretion in LPS-stimulated RAW264.7 cells through suppression of NF-κB/MAPK signaling pathway. Evidence-based Complementary and Alternative Medicine, 2017, 8248142. https://doi.org/10.1155/2017/8248142
- Lin, T. P., Chen, S. Y., Duh, P. D., Chang, L. K., & Liu, Y. N. (2008). Inhibition of the epstein-barr virus lytic cycle by andrographolide. Biological & Pharmaceutical Bulletin, 31(11), 2018–2023. https://doi.org/10.1248/bpb.31.2018
- Peng, G. Y., Zhou, F., Ding, R. L., Li, H. D., & Yao, K. (2002). Modulation of lianbizi injection (andrographolide) on some immune functions]. Zhongguo Zhong Yao Za Zhi, 27(2), 147–150.
- Raja, K., Prabahar, A., Selvakumar, S., & Raja, T. K. (2014). In silico analysis to compare the effectiveness of assorted drugs prescribed for swine flu in diverse medicine systems. Indian Journal of Pharmaceutical Sciences, 76(1), 10–18.
- Reddy, V. L., Reddy, S. M., Ravikanth, V., Krishnaiah, P., Goud, T. V., Rao, T. P., … Venkateswarlu, Y. (2005). A new bis-andrographolide ether from Andrographis paniculata nees and evaluation of anti-HIV activity. Natural Product Research, 19(3), 223–230. https://doi.org/10.1080/14786410410001709197
- Seubsasana, S., Pientong, C., Ekalaksananan, T., Thongchai, S., & Aromdee, C. (2011). A potential andrographolide analogue against the replication of herpes simplex virus type 1 in vero cells. Medicinal Chemistry, 7(3), 237–244. https://doi.org/10.2174/157340611795564268
- Sheeja, K., & Kuttan, G. (2007a). Activation of cytotoxic T lymphocyte responses and attenuation of tumor growth in vivo by Andrographis paniculata extract and andrographolide. Immunopharmacology and Immunotoxicology, 29(1), 81–93. https://doi.org/10.1080/08923970701282726
- Sheeja, K., & Kuttan, G. (2007b). Modulation of natural killer cell activity, antibody-dependent cellular cytotoxicity, and antibody-dependent complement-mediated cytotoxicity by andrographolide in normal and Ehrlich ascites carcinoma-bearing mice. Integrative Cancer Therapies, 6(1), 66–73. https://doi.org/10.1177/1534735406298975
- Shi, H., Guo, W., Zhu, H., Li, M., Ung, C. O. L., Hu, H., & Han, S. (2019). Cost-effectiveness analysis of Xiyanping injection (andrographolide sulfonate) for treatment of adult community acquired pneumonia: A retrospective, propensity score-matched cohort study. Evidence-Based Complementary and Alternative Medicine, 2019, 4510591. https://doi.org/10.1155/2019/4510591
- Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., … Xie, Q. (2020). Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. BMJ, 369, m1849. https://doi.org/10.1136/bmj.m1849
- Wang, Z. F., & Xie, Y. M. (2012). Adverse event case reports for Xiyanping injection based on literature]. Zhongguo Zhong Yao Za Zhi, 37(18), 2792–2795. https://doi.org/10.4268/cjcmm20121830
- P.-F. Wei (Ed.). (2020). Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J (Engl), 133(9), 1087–1095. https://doi.org/10.1097/CM9.0000000000000819
- Xiong, N., Wang, X., Liu, X., Chen, J., Zheng, H., Huo, Z., & Jiao, J. (2015). Effect of the combination of Xiyanping and Cefazolin on the function of neutrophils in mice]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, 32(5), 1079–1082.
- Yang, Q. W., Li, Q., Zhang, J., Xu, Q., Yang, X., Li, Z. Y., & Xu, H. (2019). Crystal structure and anti-inflammatory and anaphylactic effects of andrographlide sulphonate E in Xiyanping, a traditional Chinese medicine injection. The Journal of Pharmacy and Pharmacology, 71(2), 251–259. https://doi.org/10.1111/jphp.13028
- Zhang, J. L., Li, W. X., Li, Y., Wong, M. S., Wang, Y. J., & Zhang, Y. (2021). Therapeutic options of TCM for organ injuries associated with COVID-19 and the underlying mechanism. Phytomedicine, 85, 153297. https://doi.org/10.1016/j.phymed.2020.153297
- Zheng, D., Shao, J., Chen, W., & Luo, Y. (2016). In vitro metabolism of sodium 9-dehydro-17-hydro-andrographolide-19-yl sulfate in rat liver S9 by liquid chromatography-mass spectrometry method. Pharmacognosy Magazine, 12(Suppl 2), S102–S108. https://doi.org/10.4103/0973-1296.182194
- Zhuang, W., Fan, Z., Chu, Y., Wang, H., Yang, Y., Wu, L., … Xi, S. (2020). Chinese patent medicines in the treatment of Coronavirus Disease 2019 (COVID-19) in China. Frontiers in Pharmacology, 11, 1066. https://doi.org/10.3389/fphar.2020.01066
Citing Literature
